Comparative Pharmacology
Head-to-head clinical analysis: TRIPLE SULFA versus TRIPLE SULFAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPLE SULFA versus TRIPLE SULFAS.
TRIPLE SULFA vs TRIPLE SULFAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), blocking folate synthesis essential for nucleic acid production.
Competitive inhibition of dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication. Triple sulfas (sulfadiazine, sulfamerazine, sulfamethazine) act synergistically to inhibit folic acid synthesis.
1 g orally every 12 hours for 10 days (as sulfadiazine, sulfamethazine, and sulfamerazine combination).
1 to 2 tablets (each containing sulfadiazine 167 mg, sulfamerazine 167 mg, sulfamethazine 167 mg) orally every 4 hours initially, then 2 tablets every 6 hours. Maximum daily dose: 6 grams of total sulfonamide.
None Documented
None Documented
6-12 hours (sulfadiazine 10-13h, sulfamerazine 16-24h, sulfamethazine 7-12h); prolonged in renal impairment.
Terminal elimination half-life ranges from 10-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours) and neonates (40-120 hours).
80-90% renal (glomerular filtration and tubular secretion) as unchanged drug and acetylated metabolites; 5-10% biliary/fecal.
Primarily renal; approximately 70-100% excreted unchanged in urine via glomerular filtration and tubular secretion. Minor biliary/fecal elimination (<5%) with enterohepatic circulation possible.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic